Durvalumab - Wikipedia
Rapid Readouts: Updated Results and 5-Year Survival Outcomes From the PACIFIC Trial
Design and Rationale for a Phase III, Double-Blind, Placebo-Controlled Study of Neoadjuvant Durvalumab + Chemotherapy Followed by Adjuvant Durvalumab for the Treatment of Patients With Resectable Stages II and III non-small-cell Lung
Beyond chemoradiotherapy: improving treatment outcomes for patients with stage III unresectable non-small-cell lung cancer through immuno-oncology and durvalumab (Imfinzi®▽, AstraZeneca UK Limited) | British Journal of Cancer
PACIFIC phase III trial scheme. | Download Scientific Diagram
Durvalumab in non-small-cell lung cancer patients: current developments. | Semantic Scholar
A Phase III Study of Durvalumab (MEDI4736) With or Without Tremelimumab for Previously Treated Patients With Advanced NSCLC: Rationale and Protocol Design of the ARCTIC Study - Clinical Lung Cancer
Durvalumab vs placebo consolidation therapy after chemoradiotherapy in stage III non-small-cell lung cancer: An updated PACIFIC trial-based cost-effectiveness analysis - Lung Cancer
Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial - The Lancet
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC | NEJM
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC | NEJM
Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer | NEJM
Real world data of durvalumab consolidation after chemoradiotherapy in stage III non-small-cell lung cancer - Lung Cancer
Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial - The Lancet Oncology
Stage III NSCLC - NSCLC Treatment Paradigm - Text Module - NSCLC Practical Guidance - Oncology - Clinical Care Options
PACIFIC survival explained: Cancer spread red | EurekAlert!
Exploratory 3-year overall survival for patients with unresectable... | Download Scientific Diagram
Gerry Hanna 💙 on Twitter: "PACIFIC study - adjuvant Durvalumab demonstrates a major step change in the management of stage 3 NSCLC with a clear increase in OS #WCLC2018 @IASLC @BTOGORG #radonc @
Decision making process diagram to evaluate candidate patients for... | Download Scientific Diagram
Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study - The Lancet Oncology
Durvalumab in non-small-cell lung cancer patients: current developments | Future Oncology
PACIFIC 5-Yr Update - Capsule Summary Slidesets - Lung Cancer - 2021 ASCO Virtual Annual Meeting - Oncology - Clinical Care Options
Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial - ScienceDirect
